Being a small biotech company, Orchard focuses on key competencies internally, while engaging with bespoke service providers to deliver important aspects of their business. Niche has helped Orchard with this agile business model over several years, by generating submission-ready regulatory documents such as clinical study reports for Orchard’s HSC-based gene therapies. This ongoing collaboration underscores our proven track record in navigating the unique regulatory and clinical challenges of gene therapy development, and our shared dedication to bringing transformative treatments to patients with rare and life-threatening diseases.

From the outset, Niche's expertise aligned well with Orchard's streamlined approach to operations. Our contracting process is simple and efficient, allowing both Orchard and Niche to focus on what’s important – clinical development of pioneering gene therapies. Frequent, open, proactive communication enabled operational efficiency. Moreover, deliverables are generated according to tight regulatory timelines. The Niche team is passionate and dedicated, with extensive in-house knowledge of gene therapy. This combination of efficiency and expertise has helped Orchard to drive forward the gene therapy specialism, one of the most revolutionary fields in biotechnology.